Diagnosis and treatment of myocardial infarction in patient with end - stage renal disease on chronic hemodialysis


Cite item

Full Text

Abstract

This review represents different aspects of myocardial infarction in patient with end - stage renal disease on chronic hemodialysis. We discuss difficulties in diagnosis, optimal method of coronary revascularization, timing of hemodialysis session, medical therapy, as well as epidemiology and prognosis. There are no unambiguous answers to these problems because patients with end - stage renal disease were excluded from most of the studies.

About the authors

D. E Antukh

Sechenov First Moscow State Medical University (Sechenov University)

Email: dimst@list.ru
студент ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

D. Yu Shchekochikhin

Sechenov First Moscow State Medical University (Sechenov University)

доц. каф. профилактической и неотложной кардиологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

A. P Nesterov

Pirogov Russian National Research Medical University

доц. каф. интервенционной кардиологии и кардиореабилитации ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Moscow, Russia

M. Yu Gilarov

Pirogov Russian National Research Medical University

зав. каф. интервенционной кардиологии и кардиореабилитации ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Moscow, Russia

References

  1. Gilbertson D, Ishani A, Kasiske B.L, Liu J. Excerpts From the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2011;55(Suppl 1):2010-1. doi: 10.1053/j.ajkd.2009.10.009
  2. Herzog C.A. How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion - based medicine. J Am Soc Nephrol. 2003;14(10):2556-72. doi: 10.2308/ajpt-50738
  3. Cheung A.K, Sarnak M.J, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65(6):2380-9. doi: 10.1111/j.1523-1755.2004.00657.x
  4. Respalacios F.E.C.T, Aylor A.L.J.T, Godoa L.A.Y.A, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States 1. Kidney Int. 2002;62:1799-805. doi: 10.1046/j.1523-1755.2002.00638.x
  5. Parekh R.S, Zhang L, Fivush B.A, Klag M.J. Incidence of Atherosclerosis by Race in the Dialysis Morbidity and Mortality Study: A Sample of the US ESRD Population. J Am Soc Nephrol. 2005:1420-6. doi: 10.1681/ASN.2004080661
  6. Young B.A, Rudser K, Kestenbaum B, Seliger S.L, Andress D, Boyko E.J. Racial and ethnic differences in incident myocardial infarction in end - stage renal disease patients: The USRDS. Kidney Int. 2006;69(9):1691-8. doi: 10.1038/sj.ki.5000346
  7. Conlon P.J, Krucoff M.W, Minda S, Schumm D, Schwab S.J. Incidence and long - term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol. 1998;49(4):236-9.
  8. Go A.S, Bansal N.M.C. Chronic Kidney Disease and Risk of Presenting with Acute Myocardial Infarction versus Stable Exertional Angina in Adults with Coronary Heart Disease. NeuroImage. 2011;85(01):1-27. doi: 10.1016/j.neuroimage.2013.08.045
  9. Herzog C.A, Littrell K, Arko C, Frederick P.D, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: A collaborative project of the United States renal data system and the national registry of myocardial infarction. Circulation. 2007;116(13):1465-72. doi: 10.1161/CIRCULATIONAHA.107.696765
  10. Shroff G.R, Frederick P.D, Herzog C.A. Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163(3):399-406. doi: 10.1016/j.ahj.2011.12.002
  11. Fox C.S, Muntner P, Chen A.Y, et al. Use of evidence - based therapies in short - term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the national cardiovascular data acute coronary. Circulation. 2010;121(3):357-65. doi: 10.1161/CIRCULATIONAHA.109.865352
  12. Szummer K, Lundman P, Jacobson S.H, et al. Relation between renal function, presentation, use of therapies and in - hospital complications in acute coronary syndrome: Data from the SWEDEHEART register. J Intern Med. 2010;268(1):40-9. doi: 10.1111/j.1365-2796.2009.02204.x
  13. Surana S.P, Riella L.V, Keithi-Reddy S.R, Charytan D.M, Singh A.K. Acute coronary syndrome in ESRD patients. Kidney Int. 2009;75(5):558-62. doi: 10.1038/ki.2008.233
  14. Thygesen K, Alpert J.S, Jaffe A.S, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;1. doi: 10.1016/j.gheart.2018.08.004
  15. Dubin R.F, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross - sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14(1). doi: 10.1186/1471-2369-14-229
  16. Van der Linden N, Cornelis T, Kimenai D.M, et al. Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease. Circulation. 2017;136(11):1073-5. doi: 10.1161/CIRCULATIONAHA.117.029986
  17. Stacy S.R, Suarez-Cuervo C, Berger Z, et al. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: A systematic review. Ann Intern Med. 2014;161(7):502-12. doi: 10.7326/M14-0746
  18. Twerenbold R, Wildi K, Jaeger C, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation. 2015;131(23):2041-50. doi: 10.1161/CIRCULATIONAHA.114.014245
  19. Roffi M, Patrono C, Collet J.P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st - segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of. Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320
  20. Miller-Hodges E, Anand A, Shah A.S.V, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients with Renal Impairment Presenting with Suspected Acute Coronary Syndrome. Circulation. 2018;137(5):425-35. doi: 10.1161/CIRCULATIONAHA.117.030320
  21. Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients with Renal Dysfunction. Circulation. 2018;137(5):436-51. doi: 10.1161/CIRCULATIONAHA.117.028901
  22. Martin G.S, Becker B.N, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant. 1998;13(7):1709-12. http://www.ncbi.nlm.nih.gov/pubmed/9681716
  23. Newby L.K, Jesse R.L, Babb J.D, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2012;60(23):2427-63. doi: 10.1016/j.jacc.2012.08.969
  24. Apple F.S, Murakami M.M, Pearce L.A, Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end - stage renal disease. Circulation. 2002;106(23):2941-45. http://www.ncbi.nlm.nih.gov/pubmed/12460876
  25. Morrow D.A, Bonaca M.P. Real - world application of “delta” troponin: Diagnostic and prognostic implications. J Am Coll Cardiol. 2013;62(14):1239-41. doi: 10.1016/j.jacc.2013.06.049
  26. Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62(14):1231-8. doi: 10.1016/j.jacc.2013.06.050
  27. Tun A, Khan I.A, Win M.T, et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long - term hemodialysis patients and effect of hemodialysis on these cardiac markers. Cardiology. 1998;90(4):280-5. doi: 10.1159/000006859
  28. Lippi G, Tessitore N, Montagnana M, Salvagno G.L, Lupo A, Guidi G.C. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008;132(1):72-6. doi: 10.1043/1543-2165(2008)132[72:IOSTAU]2.0.CO;2
  29. Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end - stage renal failure. Clin Chem. 2000;46(9):1345-50.
  30. Nevis I.F, Mathew A, Novick R.J, et al. Optimal method of coronary revascularization in patients receiving dialysis: Systematic review. Clin J Am Soc Nephrol. 2009;4(2):369-78. doi: 10.2215/CJN.02640608
  31. Wang Y, Zhu S, Gao P, Zhang Q. Comparison of coronary artery bypass grafting and drug - eluting stents in patients with chronic kidney disease and multivessel disease: A meta - analysis. Eur J Intern Med. 2017;43(2016):28-35. doi: 10.1016/j.ejim.2017.04.002
  32. Möckel M, Searle J, Baberg H.T, et al. Revascularisation of patients with end - stage renal disease on chronic haemodialysis: bypass surgery versus PCI-analysis of routine statutory health insurance data. Open Hear. 2016;3(2):e000464. doi: 10.1136/openhrt-2016-000464
  33. Krishnaswami A, Mc Culloch C.E, Tawadrous M, et al. Coronary artery bypass grafting and percutaneous coronary intervention in patients with end - stage renal disease. Eur J Cardio - thoracic Surg. 2015;47(5):e193-e198. doi: 10.1093/ejcts/ezv104
  34. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan E.L. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 2015;66(11):1209-20. doi: 10.1016/j.jacc.2015.06.1334
  35. Shroff G.R, Solid C.A, Herzog C.A. Long - term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug - eluting and bare metal stents in the united states. Circulation. 2013;127(18):1861-9. doi: 10.1161/CIRCULATIONAHA.112.001264
  36. Hemmelgarn B.R, Southern D, Culleton B.F, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004;110(14):1890-5. doi: 10.1161/01.CIR.0000143629.55725.D9
  37. Chen J-J, Lin L-Y, Yang Y-H, et al. On pump versus off pump coronary artery bypass grafting in patients with end - stage renal disease and coronary artery disease - A nation - wide, propensity score matched database analyses. Int J Cardiol. 2017;227:529-34. doi: 10.1016/j.ijcard.2016.10.108
  38. Aoyama T, Ishii H, Toriyama T, et al. Sirolimus - eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J. 2008;72(1):56-60.
  39. Yachi S, Tanabe K, Tanimoto S, et al. Clinical and Angiographic Outcomes Following Percutaneous Coronary Intervention With Sirolimus-Eluting Stents Versus Bare-Metal Stents in Hemodialysis Patients. Am J Kidney Dis. 2009;54(2):299-306. doi: 10.1053/j.ajkd.2009.01.263
  40. Chang T.I, Montez-Rath M.E, Tsai T.T, Hlatky M.A, Winkelmayer W.C. Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol. 2016;67(12):1459-69. doi: 10.1016/j.jacc.2015.10.104
  41. Li S, Ye D, Chen G, Xu W. Meta-Analysis of Comparison of Drug-Eluting Stents and Bare-Metal Stents in Patients on Dialysis. Am J Cardiol. 2017;119(8):1186-92. doi: 10.1016/j.amjcard.2016.12.036
  42. Kaufman J.S, O’Connor T.Z, Zhang J.H, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14(9):2313-21.
  43. Hiremath S, Holden R.M, Fergusson D, Zimmerman D.L. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol. 2009;4(8):1347-55. doi: 10.2215/CJN.00810209
  44. Herzog C.A. The optimal method of coronary revascularization in dialysis patients: choosing between a rock and a hard place. Int J Artif Organs. 2000;23(4):215-8. http://www.ncbi.nlm.nih.gov/pubmed/ 10832653
  45. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153.
  46. Sorrell V.L. Diagnostic tools and management strategies for coronary artery disease in patients with end - stage renal disease. Semin Nephrol. 2001;21(1):13-24.
  47. Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002;89(4):450-2.
  48. Best P.J.M, Lennon R, Gersh B.J, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146(2):345-50. doi: 10.1016/S0002-8703(03)00231-X
  49. Jeremias A, Bhatt D.L, Chew D.P, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89(10):1209-11.
  50. Khaja A, Garg R, Govindarajan G, Madsen R, Aggarwal K. Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: A single center experience. Hemodial Int. 2008;12:S2-S8. doi: 10.1111/j.1542-4758.2008.00316.x
  51. Freeman R.V, Mehta R.H, Al Badr W, Cooper J.V, Kline-Rogers E, Eagle K.A. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41(5):718-24.
  52. Tsai T.T, Maddox T.M, Roe M.T, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302(22):2458-64. doi: 10.1001/jama.2009.1800
  53. Ifudu O, Miles A.M, Friedman E.A. Hemodialysis immediately after acute myocardial infarction. Nephron. 1996;74(1):104-9. doi: 10.1159/000189287
  54. Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol. 2009;4(8):1324-30. doi: 10.2215/CJN.04470908
  55. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19-62. doi: 10.1038/kisup.2012.64
  56. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. doi: 10.1056/NEJMoa043545
  57. Fellström B.C, Jardine A.G, Schmieder R.E, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi: 10.1056/NEJMoa0810177
  58. Baigent C, Landray M.J, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo - controlled trial. Lancet (London, England). 2011;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3
  59. Upadhyay A, Earley A, Lamont J.L, Haynes S, Wanner C, Balk E.M. Lipid - lowering therapy in persons with chronic kidney disease: a systematic review and meta - analysis. Ann Intern Med. 2012;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005
  60. Palmer S.C, Craig J.C, Navaneethan S.D, Tonelli M, Pellegrini F, Strippoli G.F.M. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta - analysis. Ann Intern Med. 2012;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007
  61. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta - analysis. Eur Heart J. 2013;34(24):1807-17. doi: 10.1093/eurheartj/eht065
  62. Ethier J, Bragg-Gresham J.L, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50(4):602-11. doi: 10.1053/j.ajkd.2007.07.007
  63. Chan K.E, Lazarus J.M, Thadhani R, Hakim R.M. Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients. J Am Soc Nephrol. 2009;20(4):872-81. doi: 10.1681/ASN.2008080824
  64. Palmer S.C, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Palmer S.C, ed. Cochrane Database Syst Rev. 2013;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2
  65. Foundation: NK. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney. 2005;45(4):51-3. doi: 10.1053/j.ajkd.2005.01.016
  66. Berger A.K, Duval S, Krumholz H.M. Aspirin, beta - blocker, and angiotensin - converting enzyme inhibitor therapy in patients with end - stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201-8.
  67. Knoll G.A, Sahgal A, Nair R.C, Graham J, van Walraven C, Burns K.D. Renin - angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112(2):110-4.
  68. Miskulin D, Sarnak M. A β - blocker trial in dialysis patients: Is it feasible and worthwhile? Am J Kidney Dis. 2016;67(6):822-5. doi: 10.1053/j.ajkd.2016.03.413
  69. Weir M.A, Dixon S.N, Fleet J.L, et al. β - Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis. J Am Soc Nephrol. 2015;26(4):987-96. doi: 10.1681/ASN.2014040324
  70. Struthers A, Mac Donald T.M. Review of aldosterone - and angiotensin II - induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-70. doi: 10.1016/j.cardiores.2003.11.037
  71. Quach K, Lvtvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta - analysis. Am J Kidney Dis. 2016;68(4):591-8. doi: 10.1053/j.ajkd.2016.04.011
  72. Zhao Y, Yan B, Zhao Z, Wang S, Weng X. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: A systematic review and meta - analysis. Ren Fail. 2016;38(4):589-99. doi: 10.3109/0886022X.2016.1149684
  73. Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31(6):1239-44. doi: 10.1097/HJH.0b013e32835f955c
  74. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients. J Am Coll Cardiol. 2014;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056
  75. Hammer F, Krane V, Störk S, et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant. 2014;29(2):400-5. doi: 10.1093/ndt/gft409
  76. Walsh M, Manns B, Garg A.X, et al. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol. 2015;10(9):1602-8. doi: 10.2215/CJN.12371214
  77. Herzog C.A, Ma J.Z, Collins A.J. Poor long - term survival after acute myocardial infarction among patients on long - term dialysis. N Engl J Med. 1998;339(12):799-805. doi: 10.1056/NEJM199809173391203
  78. Chertow G.M, Normand S.L, Silva L.R, Mc Neil B.J. Survival after acute myocardial infarction in patients with end - stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis. 2000;35(6):1044-51.
  79. Iseki K, Fukiyama K. Long - term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis. 2000;36(4):820-5.
  80. Baber U, Kini A.S, Sharma S.K, Kim M.C, Farkouh M.E, Muntner P. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol. 2009;103(11):1513-7. doi: 10.1016/j.amjcard.2009.01.364
  81. Michos E.D, Wilson L.M, Yeh H-C, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta - analysis. Ann Intern Med. 2014;161(7):491-501. doi: 10.7326/M14-0743
  82. Hickson L.J, Cosio F.G, El-Zoghby Z.M, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. Am J Transplant. 2008;8(11):2352-9. doi: 10.1111/j.1600-6143.2008.02395.x
  83. Havekes B, van Manen J.G, Krediet R.T, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2006;47(5):823-9. doi: 10.1053/j.ajkd.2006.01.019
  84. Mc Gill D, Talaulikar G, Potter J.M, Koerbin G, Hickman P.E. Over time, high - sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis - dependent chronic renal failure. Clin Chim Acta. 2010;411(13-14):936-9. doi: 10.1016/j.cca.2010.03.004
  85. Hassan H.C, Howlin K, Jefferys A, et al. High-Sensitivity Troponin as a Predictor of Cardiac Events and Mortality in the Stable Dialysis Population. Clin Chem. 2014;60(2):389-98. doi: 10.1373/clinchem.2013.207142
  86. Lentine K.L, Costa S.P, Weir M.R, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434-80. doi: 10.1016/j.jacc.2012.05.008

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies